CDK2 and cancer: In our study, in addition to confirming that CDK2 is a marker of poor prognosis, we have found that this gene harbors genomic amplifications and splice mutation and that its expression: (i) is upregulated in OSCC patients; (ii) correlates with cancer grade; and (iii) is associated to HPV infection.